Lamivudine/Zidovudine Aurobindo (Zidovudine, Lamivudine)

Both lamivudine and zidovudine are nucleoside analogues that are converted inside cells to active triphosphate forms. These active metabolites inhibit HIV reverse transcriptase, causing premature termination of viral DNA synthesis and preventing the virus from replicating.

The specific dose and dosing schedule of Lamivudine/Zidovudine are determined by the prescribing healthcare professional based on the patient’s age, weight, renal function, and overall treatment plan. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been fully established. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine/Zidovudine is a fixed‑dose combination of two NRTIs, offering the convenience of a single tablet compared with separate agents. It is generally used in first‑line regimens, whereas newer agents such as integrase inhibitors may provide different efficacy or side‑effect profiles. Choice of therapy depends on resistance patterns, patient tolerance and clinical guidelines.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lamivudine/Zidovudine is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include lactic acidosis, severe hepatomegaly with steatosis, bone‑marrow suppression leading to anemia or neutropenia, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained fatigue, abdominal pain, rapid weight loss, or severe skin reactions.

Patients with known hypersensitivity to lamivudine, zidovudine, or any excipients in the formulation should avoid this medication. It is also contraindicated in individuals with severe bone‑marrow failure or those who cannot be monitored regularly for hematologic toxicity.